$0.94
5.61% yesterday
Nasdaq, Sep 12, 10:00 pm CET
ISIN
US00444T1007
Symbol
TLPH

AcelRx Pharmaceuticals, Inc. Stock price

$0.94
+0.52 123.65% 1M
+0.39 70.51% 6M
+0.42 79.36% YTD
+0.04 4.44% 1Y
-4.09 81.30% 3Y
-24.26 96.27% 5Y
-77.86 98.81% 10Y
-90.06 98.97% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.06 5.61%
ISIN
US00444T1007
Symbol
TLPH
Industry

Key metrics

Basic
Market capitalization
$20.4m
Enterprise Value
$13.7m
Net debt
positive
Cash
$6.8m
Shares outstanding
20.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
681.3 | 742.2
EV/Sales
455.0 | 495.6
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
43.9%
Return on Equity
-162.5%
ROCE
-96.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$30.0k | $27.5k
EBITDA
- | -
EBIT
$-13.4m | $-16.7m
Net Income
$-11.3m | $-10.5m
Free Cash Flow
$-11.6m
Growth (TTM | estimate)
Revenue
-92.5% | -
EBITDA
- | -
EBIT
-12.6% | -9.2%
Net Income
-16.6% | 19.5%
Free Cash Flow
19.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-49,459.3%
Net
-41,870.4% | -38,000.0%
Free Cash Flow
-42,992.6%
More
EPS
$-0.3
FCF per Share
$-0.6
Short interest
2.2%
Employees
13
Rev per Employee
$0.0
Show more

Is AcelRx Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

AcelRx Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AcelRx Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from AcelRx Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.03 0.03
93% 93%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.34 7.34
1% 1%
24,467%
- Research and Development Expense 6.05 6.05
24% 24%
20,167%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
13% 13%
-44,513%
Net Profit -11 -11
17% 17%
-37,700%

In millions USD.

Don't miss a Thing! We will send you all news about AcelRx Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AcelRx Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
5 days ago
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The com...
Neutral
GlobeNewsWire
5 days ago
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-marke...
Neutral
PRNewsWire
19 days ago
The NEPHRO CRRT pivotal trial has now reached approximately 25% enrollment, driven by the recent acceleration in the recruitment rate from new profile clinical sites On track for planned study completion by the end of 2025 SAN MATEO, Calif. , Aug. 25, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercializa...
More AcelRx Pharmaceuticals, Inc. News

Company Profile

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Head office United States
CEO Vincent Angotti
Employees 13
Founded 2005
Website talphera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today